[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351159-105":59,"doc-detail-351159-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","ctdna-guided-management-of-pole-mutant-gi-malignancies-promotes-exceptional-responses-and-prolonged-survival-to-immunotherapy","ctDNA guided management of POLE mutant GI malignancies promotes exceptional responses and prolonged survival to immunotherapy","","Patients with unresectable gastrointestinal cancers, including advanced colorectal and gallbladder cancer, face limited options and frequent therapeutic resistance to chemotherapy. Immune checkpoint inhibitors benefit only a subset of metastatic colorectal cancer and a portion of gallbladder cancer, creating a need for predictive biomarkers to improve patient selection. This original research highlights liquid-biopsy ctDNA to guide immunotherapy for rare POLE mutations, reporting complete metabolic response, radiologic responses, and extended survival in reported cases. The work supports shared multidisciplinary decision-making for personalised care.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ctdna-guided-management-of-pole-mutant-gi-malignancies-promotes-exceptional-responses-and-prolonged-survival-to-immunotherapy/351159/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ctdna-guided-management-of-pole-mutant-gi-malignancies-promotes-exceptional-responses-and-prolonged-survival-to-immunotherapy/351159.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"What POLE mutation type is emphasized in the study?","Question",{"text":112,"@type":113},"The focus is on DNA polymerase epsilon (POLE) exonuclease domain mutations (POLE EDM). These are described as rare but identified across several malignancies, including colorectal and gallbladder cancers.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},351159,1790483297,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":131,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":132,"faqs":133,"seo_title":134,"seo_description":67,"update_tm":135,"read_time":136,"preview_page_count":19,"preview_urls":137},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","TYPE Original Research PUBLISHED 17 February 2026  \nDOI 10.3389/fimmu.2026.1738295  \nOPEN ACCESS  \nEDITED BY  \nAsgar Ali,  \nAll India Institute of Medical Sciences (Patna), India  \nREVIEWED BY  \nShixiang Wang,  \nCentral South University, China Ramadhani Chambuso,  \nSchool of Public Health and Harvard University, United States  \n*CORRESPONDENCE  \nKhurum Khan  \n [khurum.khan1@nhs.net](khurum.khan1@nhs.net)  \nRECEIVED 03 November 2025  \nREVISED 30 January 2026  \nACCEPTED 02 February 2026  \nPUBLISHED 17 February 2026  \nCITATION  \nMahmood U, Bhan C, Imber C, Murphy J, Menon K, Barwick TD, Amin Zand Khan K (2026) ctDNA guided management of POLE  \nmutant GI malignancies promotes exceptional responses and prolonged survival to immunotherapy.  \nFront. Immunol. 17:1738295 .  \ndoi: 10.3389/fimmu.2026.1738295  \nCOPYRIGHT  \n© 2026 Mahmood, Bhan, Imber, Murphy, Menon, Barwick, Amin and Khan. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nctDNA guided management of POLE mutant GI malignancies promotes exceptional responses and prolonged survival to immunotherapy  \nUmair Mahmood 1, Chetan Bhan 2, Charles Imber 2, Jamie Murphy 2, Krish Menon 2, Tara D. Barwick 3,4, Zahir Amin 4,5 and Khurum Khan 1,4,6*  \n1 Department of Gastrointestinal Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, 2Cleveland Clinic London, London, United Kingdom, 3 Imperial College Healthcare NHS Trust, London, United Kingdom, 4The London Clinic, London, United Kingdom,  \n5 Department of Radiology, University College Hospital NHS Foundation Trust, London, United Kingdom, 6 HCA Healthcare UK, London, United Kingdom  \nPatients with unresectable Gastrointestinal cancers (GI) including advanced colorectal cancer (CRC) and gall bladder cancer (GBC) have limited treatment options. Treatment with chemotherapy is associated with limited success resulting from therapeutic resistance . Immune checkpoint inhibitors are effective for a subset of metastatic CRC (5% with MSI-H status) and up to 30% of patients with GBC. Therefore, there is an urgent unmet need to discover new predictive biomarkers to aid patient selection for ICIs with a demonstrated clinical value in a challenging patient population. We highlight the utility of a liquid biopsy approach to aid selection of GI cancer patients harbouring rare POLE mutations for immunotherapy, leading to complete metabolic response in addition to radiologic responses and extended survival in all three patients. This study advocates for specialised multi-disciplinary teams performing shared clinical decision making to advance personalised care and improve outcomes of a subset of GI cancer patients with a poor prognosis.  \nKEYWORDS  \ncolorectal cancer, ctDNA, gall bladder cancer, immunotherapy, pole  \nIntroduction  \nPatients with GI cancers represent a clinical population with poor outcomes after conventional treatments and represent an active avenue of investigation to meet a major medical need. Immune checkpoint inhibitors (ICIs) targeting the programmed death-1 (PD-1) protein have shown signiﬁcant efﬁcacy and are now the treatment of choice for patients with mismatch repair-deﬁcient (dMMR) metastatic colorectal cancer (1) and offer modest beneﬁt in patients with biliary tract cancers when combined with chemotherapy. However, dMMR accounts for only a small subset of cases and despite advancements in systemic treatments such as immunotherapy, a paucity of additional validated predictive  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nbiomarkers in these GI malignancies can limit the p","cbCaiotCj0cKuEdL","https://ap.wps.com/l/cbCaiotCj0cKuEdL","pdf",3816786,"English","# Introduction\n# Liquid biopsy and POLE rationale\n# Study approach and clinical management","[{\"question\":\"What POLE mutation type is emphasized in the study?\",\"answer\":\"The focus is on DNA polymerase epsilon (POLE) exonuclease domain mutations (POLE EDM). These are described as rare but identified across several malignancies, including colorectal and gallbladder cancers.\"}]","ctDNA guided management of POLE mutant GI malignancies promotes exceptional responses and prolonged survival to immunotherapy | PDF",1790092857,23,[138,142,146,150],{"page_no":8,"url":139,"width":140,"height":141},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4ea94a94b532ffbb67e1e0464010845.webp",983,1389,{"page_no":14,"url":143,"width":144,"height":145},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e898ce849e6db85a23ecb56082f82d79.webp",982,1388,{"page_no":81,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c907793427635ae4ea45278454fa5f7.webp",981,1386,{"page_no":19,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a94711d9bbbb650b37d8d2cc67c4ba6.webp",980,1385]